Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study to Assess the Efficacy and Safety of Nelonemdaz in Patients With Acute Ischemic Stroke

X
Trial Profile

A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study to Assess the Efficacy and Safety of Nelonemdaz in Patients With Acute Ischemic Stroke

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Mar 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nelonemdaz (Primary)
  • Indications Stroke
  • Focus Registrational; Therapeutic Use
  • Acronyms RODIN
  • Sponsors GNT Pharma
  • Most Recent Events

    • 10 Feb 2023 As per trial design presented at the International Stroke Conference 2023, n= 210 patients have been enrolled by August 23, 2022. It is expected that enrollment could be finalized until spring season of 2023.
    • 10 Feb 2023 Rationale and trial design presented at the International Stroke Conference 2023.
    • 19 Sep 2022 According to a GNT Pharma media release, the trial has now enrolled more than 224 patients over the last 7 months and is expected to complete enrollment in the middle of 2023.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top